Author:
Cazaentre T.,Morschhauser F.,Vermandel M.,Betrouni N.,Prangère T.,Petyt G.,Steinling M.,Huglo D.
Subject
Radiology Nuclear Medicine and imaging,Radiological and Ultrasound Technology,Biophysics
Reference41 articles.
1. Radioimmunotherapy of non-Hodgkin's lymphoma with 90YDOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?;Sharkey;J Nucl Med,2003
2. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab;Linden;Clin Cancer Res,2005
3. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma;Griffiths;J Nucl Med,2003
4. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma;Emmanouilides;Leuk Lymphoma,2006
5. Fractionated radioimmunotherapy in NHL with DOTA-conjugated, humanized anti-CD22 IgG, epratuzumab: results at high cumulative doses of 90Y;Kraeber-Bodere;J Clin Oncol,2008